Rapid Micro Biosystems (NASDAQ:RPID) Releases Earnings Results, Misses Estimates By $0.06 EPS

Rapid Micro Biosystems (NASDAQ:RPID) posted its quarterly earnings data on Wednesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.06), Zacks reports. Rapid Micro Biosystems had a negative return on equity of 113.87% and a negative net margin of 145.81%.The business had revenue of $8.00 million for the quarter, compared to analyst estimates of $7.60 million.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Revenue and placements improved. Q1 revenue rose 11% year over year to $8 million, driven by 6 Growth Direct system placements, record consumables growth, and stronger recurring revenue, which reached 63% of total revenue.
• Gross margin is improving and expected to keep rising. First-quarter gross margin was 5%, up 8 points from Q4 2025, and management expects positive product gross margin in Q2 with full-year gross margin around 20% and a mid-20% exit rate in Q4.
• MilliporeSigma partnership is expanding the opportunity. Management said the collaboration is broadening placement opportunities, adding exclusive validation/maintenance services for MilliporeSigma-sold systems, and could also support future sourcing and supply agreement benefits.
• Demand pipeline appears healthy, especially in Asia and large accounts. The company highlighted strong engagement with large biopharma customers, first-system placement in China, and growing interest in enterprise-wide automation across the Asia-Pacific region.
• 2026 guidance was reaffirmed despite a larger Q1 loss and cash usage. Rapid Micro maintained full-year revenue guidance of $37 million-$41 million and 30-38 system placements, while Q1 net loss widened to $14.3 million and cash fell to $23 million, though management said liquidity remains supported by a $25 million credit facility.

Rapid Micro Biosystems Stock Performance

Rapid Micro Biosystems stock traded down $0.18 during trading hours on Friday, hitting $2.14. The company had a trading volume of 139,077 shares, compared to its average volume of 239,482. The firm has a market cap of $97.24 million, a PE ratio of -1.91 and a beta of 1.52. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.31 and a quick ratio of 2.36. Rapid Micro Biosystems has a one year low of $2.01 and a one year high of $4.94. The firm has a 50-day moving average of $2.62 and a 200 day moving average of $3.34.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rapid Micro Biosystems has a consensus rating of “Hold” and an average target price of $8.00.

Insider Buying and Selling at Rapid Micro Biosystems

In other Rapid Micro Biosystems news, CEO Robert G. Jr. Spignesi sold 38,327 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $3.89, for a total value of $149,092.03. Following the transaction, the chief executive officer directly owned 1,187,770 shares of the company’s stock, valued at $4,620,425.30. This represents a 3.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sean M. Wirtjes sold 17,254 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $3.92, for a total transaction of $67,635.68. Following the completion of the transaction, the chief financial officer directly owned 563,674 shares in the company, valued at approximately $2,209,602.08. This represents a 2.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 95,989 shares of company stock valued at $385,365 in the last three months. 12.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RPID. American Century Companies Inc. grew its position in shares of Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after purchasing an additional 5,341 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Rapid Micro Biosystems during the 4th quarter worth approximately $71,000. Barclays PLC acquired a new position in shares of Rapid Micro Biosystems during the 4th quarter worth approximately $72,000. XTX Topco Ltd acquired a new position in shares of Rapid Micro Biosystems during the 2nd quarter worth approximately $144,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Rapid Micro Biosystems during the 4th quarter worth approximately $160,000. 52.60% of the stock is owned by institutional investors.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.